Artis BioSolutions, an advanced therapies company integrating specialized technologies, infrastructure, and manufacturing capabilities for next-gen genetic medicines, established new synthetic DNA manufacturing capabilities in Boston utilizing Syngoi Technologies’ enzymatic platform. 

This expansion strategically extends Artis’ regional capabilities, integrating with its advanced therapy development and GMP manufacturing facility in Watertown, MA, to deliver reliable, scalable, services to its global customer base.

Brian Neel, CEO of Artis, said, “Establishing U.S.-based synthetic DNA manufacturing is a pivotal step in the evolution of the Artis platform and reinforces our mission to integrate specialized technologies — from synthetic DNA through GMP manufacturing — into a seamless, end-to-end offering. By offering Syngoi Technologies at our U.S. site, we are delivering a much needed capability to our customers focused on early development through clinical manufacturing while strengthening our global operational resilience.”

By operating production hubs on both sides of the Atlantic, Artis aims to provide enhanced service continuity and a more secure supply chain for its global partners. This dual-sourcing strategy across the U.S. and Europe aims to reduce lead times and logistics costs while mitigating the geopolitical and operational risks associated with single-region sourcing. 

“Julen Oyarzabal, CSO of Syngoi, added, “Establishing this new U.S.-based manufacturing site is a natural extension of that mission. Operating in the premier biotechnology innovation ecosystem of the greater Boston area, allows us to respond more rapidly to regional customer demand while maintaining the continuity and technical excellence of our European operations,” said José Vicente Pons Andreu, CEO of Syngoi.

Syngoi’s enzymatic platform

Syngoi’s enzymatic platform is designed to enable the rapid production of clinical-grade synthetic DNA through a cell-free cGMP process. By replacing traditional plasmid-based bacterial fermentation with an enzymatic approach, Syngoi aims to provide a more predictable, high-purity supply of genetic material with significantly reduced lead times.